Thursday, January 03, 2008 1:29:06 PM
GNVC, a few questions.
1) How did they get away with changing the trial primamry after having unblinded about 1/6 of the patients? Would the FDA re-run the data w/o these events?
2) If I can count tics, the early unblinding after the 51'st patient was treated had 15 events. [Correction, it is 12 events] Not all that significant (OS HR was p=.15).
3) Where does the 42% OS gain come from? It's not on the poster for this data:
http://www.genvec.com/download/ASCO%202007%20Poster%20Handout%20FINAL%20OUT.pdf
They do show a nice median OS benifit, but most of that benifit is driven by a single patient.
Anyway, best of luck here. Just don't bet the farm on the N=92 interim data
1) How did they get away with changing the trial primamry after having unblinded about 1/6 of the patients? Would the FDA re-run the data w/o these events?
2) If I can count tics, the early unblinding after the 51'st patient was treated had 15 events. [Correction, it is 12 events] Not all that significant (OS HR was p=.15).
3) Where does the 42% OS gain come from? It's not on the poster for this data:
http://www.genvec.com/download/ASCO%202007%20Poster%20Handout%20FINAL%20OUT.pdf
They do show a nice median OS benifit, but most of that benifit is driven by a single patient.
Anyway, best of luck here. Just don't bet the farm on the N=92 interim data
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
